Search
Selumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigational[A193533] Following its initial FDA approval on April 10, 2020,[L49991] and Health Canada approval on August 23, 2022,[L49986] the regulatory landscape has evolved. … Most recently, on November 20, 2025, the FDA expanded this indication to include adults [L53881]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: Koselugo Hard Capsules 10 mg, Koselugo Hard Capsules 25 mgRavulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigationalRavulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. … [L39690] Ravulizumab was engineered from [eculizumab], another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration.
Products: Ultomiris 300 mg/3 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (1 adet), ULTOMIRIS ® RAVULIZUMAB 100MG/ML.Elranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigational[L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]
Products: Elrexfio 44 mg/1,1 ml Enjeksiyonluk Çözelti, 1 ADET, Elrexfio 76 mg/1,9 ml Enjeksiyonluk Çözelti, 1 ADETAlbutrepenonacog alfa
go.drugbank.com/drugs/DB13884ApprovedIt is currently marketed in the forms of 250, 500, 1000 and 2000 IU/vial.[L2305] … [A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016.
Synonyms: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)Products: ไอเดลวิออน 500, IDELVION 1000 IU powder and solvent for solution for injectionTenapanor
go.drugbank.com/drugs/DB11761ApprovedInvestigational[L8558] It was first designed and synthesized in 2012. … [A185492] As an inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3) transporter, it is the first and currently only medication within its class[A185489,A185492,A185495] and therefore exists as
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: XPHOZAH 10 mg, XPHOZAH 20 mgRozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigational[L47122] Rozanolixizumab was also approved by the European Commission on January 5, 2024.[L50973] … Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P) targeting the immunoglobulin G (IgG).
Products: Rystiggo 280 mg/2 ml Enjeksiyonluk Çözelti, 1 adetInclisiran
go.drugbank.com/drugs/DB14901ApprovedInvestigational[A225953,A225958] Lowering circulating plasma LDL-C levels offers an additional benefit of reducing the risk of cardiovascular disease (CVD) and improving cardiovascular outcomes, as hypercholesterolemia … [L28178] Inclisiran was later approved by the FDA on December 22, 2021, for the treatment of heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease in adults
Products: LEQVIO SOLUTION FOR INJECTION IN PREFILLED SYRINGE 284 MG/1.5 ML, LYPTİMZİA 284 MG/1,5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETOlopatadine
go.drugbank.com/drugs/DB00768ApprovedIt is a structural analog of [doxepin], which has a minimal anti-allergic activity. … An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: OLOPATADINE HYDROCHLORIDE TABLETS 5 MG MEIJI, PALLADA-NS %6.65 MG/ML NAZAL SPREY, 30 MLDisulfiram
go.drugbank.com/drugs/DB00822ApprovedInvestigationalA carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: bis(diethylthiocarbamoyl) disulfideAflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[A261130,L47915] Ziv-aflibercept, under the brand name Zaltrap, was developed as an intravenous injection for the treatment of metastatic colorectal cancer, and it was approved by the FDA and EMA in … [L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023.
Products: EYLEA 40 MG/ML INTRAVITREAL ENJEKSIYON ICIN COZELTI ICEREN FLAKON, 1 ADET, ZALTRAP 200 MG/8 ML IV İNFÜZYONLUK KONSANTRE ÇÖZELTİ İÇEREN FLAKON, 1ADET